Vamil Devan, a Guggenheim Securities analyst specializing in the pharmaceutical sector, dives into pressing market dynamics. He discusses Nvidia's alarming plunge into correction territory and its implications for investors. Devan also analyzes President-elect Trump’s critique of pharmacy benefit managers, poised to reshape drug pricing strategies. With insights on Pfizer’s future amidst market pressures and evolving healthcare innovations, the conversation highlights a cautious outlook for major health companies facing heightened scrutiny.